TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05877963: Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Sponsor: TG Therapeutics, Inc. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 800 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,242,392

Rescue Site Savings

+$2,809,896

Unlock Full NCT05877963 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05877963 Rescue Dossier →